Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$61.74

-0.61 (-0.98%)

, UNH

UnitedHealth

$136.62

0.15 (0.11%)

14:33
10/07/16
10/07
14:33
10/07/16
14:33

UnitedHealth plans to cover Sarepta's Exondys 51, Reuters reports

A spokesperson for UnitedHealth (UNH) confirms the insurer plans to cover Sarepta Therapeutics' (SRPT) Duchenne muscular dystrophy drug Exondys 51, according to Reuters.

SRPT

Sarepta

$61.74

-0.61 (-0.98%)

UNH

UnitedHealth

$136.62

0.15 (0.11%)

  • 18

    Oct

  • 06

    Nov

SRPT Sarepta
$61.74

-0.61 (-0.98%)

09/28/16
JMPS
09/28/16
NO CHANGE
JMPS
Street underestimating price of Sarepta drug, says JMP Securities
JMP Securities analyst Liisa Bayko expects the price of Sarepta's Exondys 51 drug will be above the company's projected annual net price of $300,000. She thinks that the price will come in "closer to $538,000 per year on a gross basis, $457,000 net of discounts and compliance." The analyst raised her price target on the shares to $90 from $60 and keeps an Outperform rating on the stock.
10/04/16
PIPR
10/04/16
NO CHANGE
Target $68
PIPR
Overweight
Piper Jaffray ups Sarepta target to $68 on Summit deal
Piper Jaffray analyst Edward Tenthoff raised his price target for Sarepta Therapeutics (SRPT) to $68 from $64 after the company licensed Summit Therapeutics' (SMMT) ezutromid to treat Duchenne Muscular Dystrophy in Europe, Turkey and the Commonwealth of Independent States. The deal is a smart way for Sarepta to capitalize on its lead in DMD with the recent FDA approval of Exondys51, Tenthoff tells investors in an intraday research note. His new price target of $68 reflects the value of ezutromid. Tenthoff reiterates an Overweight rating on Sarepta. The stock is up 1% to $61.61 in late morning trading. Summit is up 94%, or $8.17, to $16.82.
10/05/16
ADAM
10/05/16
NO CHANGE
Target $28
ADAM
Buy
Summit Therapeutics price target raised to $28 from $14 at Canaccord
Canaccord analyst Arinda Lee raised her price target on Summit Therapeutics (SMMT) to $28 from $14 following the announcement of its collaboration and licensing agreement with Sarepta Therapeutics (SRPT). The deal calls for Sarepta to gain EU commercialization rights to Summit's pipeline of oral utrophin modulators for all patients with Duchenne muscular dystrophy. Lee reiterated her Buy rating Summit Therapeutics shares.
10/07/16
BARD
10/07/16
NO CHANGE
Target $102
BARD
Outperform
Anthem policy does not mean insurer not covering Sarepta drug, says Baird
Baird analyst Brian Skorney noted Anthem (ANTM) has categorized Sarepta (SRPT) Duchenne muscular dystrophy drug Exondys 51 as "not medically necessary" in a new coverage policy, but he cautions this "does not mean that Anthem is not covering the drug." The analyst explains that the policy means prior authorization requirements may be stricter, but he "highly doubts" that eligible patients will be denied coverage. Skorney, who adds that other large insurers appear to have favorable coverage for the drug, keeps an Outperform rating and $102 price target on Sarepta shares.
UNH UnitedHealth
$136.62

0.15 (0.11%)

09/13/16
CHLM
09/13/16
NO CHANGE
CHLM
LabCorp impact from Quest-Optum collaboration limited, says Craig-Hallum
Craig-Hallum analyst Bill Bonello said the Quest Diagnostics (DGX) and Optum, a division of United Healthcare (UNH), collaboration does not put LabCorp's (LH) revenue at risk. The collaboration does not create any lab benefit management service, or a preferred lab network with Quest at the hub, that would drive business to Quest labs or compete with Labcorp's Beacon LBS lab management business, the analyst wrote. Bonellow said UnitedHealthcare and LabCorp continue to work together to expand the Beacon LBS model to other markets and we would expect to see the Beacon lab network expand to other payors overtime. Also, the analyst said the collaboration does not impact LabCorp's contract with UnitedHealthcare, or UHC, and and has no impact on that contract today and does not imply a change to UHC's contracting strategy going forward. Bonello rates LabCorp a Buy with a $160 price target.
09/14/16
ADAM
09/14/16
NO CHANGE
Target $155
ADAM
Buy
LabCorp weakness a buying opportunity, says Canaccord
Canaccord analyst Mark Massaro noted LabCorp (LH) shares sold off yesterday on news that its rival, Quest Diagnostics (DGX), announced a partnership with Optum, a subsidiary of UnitedHealth (UNH). The analyst said LabCorp does not believe Quest can wrestle away UnitedHealth's long-standing lab services contract when it goes up for renewal in 2018. Massaro expects LabCorp to deliver steady quarterly beats and said the company is well positioned to capture its losses in the second half of 2016. Massaro reiterated his Buy rating and $155 price target on LabCorp shares.
09/22/16
PIPR
09/22/16
NO CHANGE
Target $155
PIPR
Overweight
UnitedHealth won VA contract worth $1B per year, says Piper Jaffray
Piper Jaffray analyst Sean Wieland says UnitedHealth unit Optum has won a contract with the U.S. Department of Veterans Affairs to provide medical disability examinations. The analyst estimates the contract, awarded to Optum wholly owned subsidiaries Logistics Health and Medical Support Los Angeles, represents $1B per year. Wieland estimates the award will be neutral to earnings in year one and become accretive in 2018. He reiterates an Overweight rating on UnitedHealth shares with a $155 price target.
09/22/16
EVER
09/22/16
INITIATION
Target $155
EVER
Buy
UnitedHealth initiated with a Buy at Evercore ISI
Evercore ISI initiated UnitedHealth with a Buy and a $155 price target.

TODAY'S FREE FLY STORIES

UPLD

Upland Software

$17.07

0.16 (0.95%)

09:19
04/24/17
04/24
09:19
04/24/17
09:19
Earnings
Upland Software raises FY17 revenue view to $87.0M-$91.0M, consensus $84.18M »

Upland announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

09:19
04/24/17
04/24
09:19
04/24/17
09:19
Hot Stocks
Breaking Hot Stocks news story on Halliburton »

Halliburton sees Q2 North…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 01

    May

  • 01

    May

  • 17

    May

SPX

S&P 500

, VIX

Volatility Index S&P 500 Options

$11.48

-3.15 (-21.53%)

09:19
04/24/17
04/24
09:19
04/24/17
09:19
Options
Overnight activity included 387 trades in SPX and 61 trades in VIX »

387 trades were executed…

SPX

S&P 500

VIX

Volatility Index S&P 500 Options

$11.48

-3.15 (-21.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHKP

Check Point

$103.41

0.77 (0.75%)

09:18
04/24/17
04/24
09:18
04/24/17
09:18
Recommendations
Check Point analyst commentary  »

Check Point price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

  • 12

    Jun

TWTR

Twitter

09:17
04/24/17
04/24
09:17
04/24/17
09:17
Recommendations
Twitter analyst commentary  »

Twitter can beat Q1 but…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPLD

Upland Software

$17.07

0.16 (0.95%)

09:17
04/24/17
04/24
09:17
04/24/17
09:17
Hot Stocks
Upland Software acquires RightAnswers »

Upland Software announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAS

Hasbro

$96.03

0.02 (0.02%)

09:16
04/24/17
04/24
09:16
04/24/17
09:16
Hot Stocks
Hasbro says has 'right brands, right team' to drive blueprint »

Regarding any potential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 18

    May

  • 31

    May

ADI

Analog Devices

$77.63

-1.03 (-1.31%)

, LLTC

Linear Technology

09:15
04/24/17
04/24
09:15
04/24/17
09:15
Upgrade
Analog Devices, Linear Technology rating change  »

Analog Devices upgraded…

ADI

Analog Devices

$77.63

-1.03 (-1.31%)

LLTC

Linear Technology

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

HAL

Halliburton

09:12
04/24/17
04/24
09:12
04/24/17
09:12
Hot Stocks
Halliburton says momentum building in North America »

Says believes a bottom…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 01

    May

  • 01

    May

  • 17

    May

GM

General Motors

09:12
04/24/17
04/24
09:12
04/24/17
09:12
Recommendations
General Motors analyst commentary  »

General Motors Q1 likely…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

HAL

Halliburton

09:11
04/24/17
04/24
09:11
04/24/17
09:11
Hot Stocks
Halliburton says seeing customers deferring new projects »

Says customers more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 01

    May

  • 01

    May

  • 17

    May

ALKS

Alkermes

$56.57

-0.16 (-0.28%)

, ACOR

Acorda Therapeutics

$15.85

-0.1 (-0.63%)

09:10
04/24/17
04/24
09:10
04/24/17
09:10
Recommendations
Alkermes, Acorda Therapeutics analyst commentary  »

Alkermes 2019 earnings…

ALKS

Alkermes

$56.57

-0.16 (-0.28%)

ACOR

Acorda Therapeutics

$15.85

-0.1 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 27

    Apr

  • 27

    Apr

  • 03

    May

  • 06

    Jun

  • 08

    Jun

WTKWY

Wolters Kluwer

$41.04

-0.83 (-1.98%)

09:09
04/24/17
04/24
09:09
04/24/17
09:09
Hot Stocks
Wolters Kluwer to explore strategic alternatives for Corsearch »

Wolters Kluwer announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$47.06

-0.63 (-1.32%)

09:09
04/24/17
04/24
09:09
04/24/17
09:09
Hot Stocks
Halliburton says not chasing market share at cost of pricing »

Says seeing sufficient…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 01

    May

  • 01

    May

  • 17

    May

GOGO

Gogo

$12.34

0.49 (4.14%)

09:09
04/24/17
04/24
09:09
04/24/17
09:09
Hot Stocks
Gogo signs new capacity deal with SES »

SES announced that Gogo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

GLD

SPDR Gold Trust

$122.31

0.35 (0.29%)

, SLV

iShares Silver Trust

$17.02

-0.04 (-0.23%)

09:08
04/24/17
04/24
09:08
04/24/17
09:08
Technical Analysis
Indexes and Sectors breakout above pivot highs and lows »

The major index ETFs,…

GLD

SPDR Gold Trust

$122.31

0.35 (0.29%)

SLV

iShares Silver Trust

$17.02

-0.04 (-0.23%)

TLT

iShares 20+ Year Treasury Bond Fund

XLF

Financial Select Sector

$23.16

-0.24 (-1.03%)

SPY

SPDR S&P 500 ETF Trust

$234.59

-0.75 (-0.32%)

DIA

Diamonds Fund ETF

$205.25

-0.26 (-0.13%)

IWM

iShares Trust Russell 2000 Index Fund

$137.21

-0.31 (-0.23%)

XLV

Health Care Select Sector SPDR

$73.68

-0.44 (-0.59%)

XLE

Energy Select Sector SPDR

$67.79

-0.34 (-0.50%)

XLK

Technology Select Sector SPDR

$53.17

-0.11 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGNX

Progenics

$7.75

-0.38 (-4.67%)

09:08
04/24/17
04/24
09:08
04/24/17
09:08
Recommendations
Progenics analyst commentary  »

Needham remains a buyer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

ADMS

Adamas Pharmaceuticals

$15.57

-0.05 (-0.32%)

09:08
04/24/17
04/24
09:08
04/24/17
09:08
Hot Stocks
Adamas: ADS-5012 data confirms reduction in levodopa-induced dyskinesia »

Adamas Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 24

    Aug

AMZN

Amazon.com

$898.53

-3.53 (-0.39%)

09:07
04/24/17
04/24
09:07
04/24/17
09:07
Hot Stocks
Amazon launches self-service marketplace for subscription providers »

Amazon.com announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 16

    May

  • 23

    May

HRS

Harris

$110.27

0.32 (0.29%)

09:06
04/24/17
04/24
09:06
04/24/17
09:06
Hot Stocks
Harris awarded 5-year, $875M ceiling multi-award IDIQ contract by USAF »

Harris has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

HEI

Heico

$69.54

0.7 (1.02%)

09:06
04/24/17
04/24
09:06
04/24/17
09:06
Hot Stocks
Heico announces 25% increase in credit facility »

HEICO Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VECO

Veeco

$31.00

0.6 (1.97%)

, UTEK

Ultratech

$30.01

0.13 (0.44%)

09:06
04/24/17
04/24
09:06
04/24/17
09:06
Recommendations
Veeco, Ultratech analyst commentary  »

Veeco price target raised…

VECO

Veeco

$31.00

0.6 (1.97%)

UTEK

Ultratech

$30.01

0.13 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

BBOX

Black Box

$9.95

-0.25 (-2.45%)

, FSTR

L.B. Foster

$13.40

-0.15 (-1.11%)

09:05
04/24/17
04/24
09:05
04/24/17
09:05
Hot Stocks
Black Box names David Russo as SVP, CFO, Treasurer »

Black Box Corporation…

BBOX

Black Box

$9.95

-0.25 (-2.45%)

FSTR

L.B. Foster

$13.40

-0.15 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 09

    May

CDW

CDW

$57.76

-0.42 (-0.72%)

09:05
04/24/17
04/24
09:05
04/24/17
09:05
Initiation
CDW initiated  »

CDW initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

RILY

B. Riley Financial

$14.75

-0.05 (-0.34%)

09:04
04/24/17
04/24
09:04
04/24/17
09:04
Hot Stocks
B. Riley Financial acquires rights to manage Dialectic hedge funds »

B. Riley Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.